Technical analysis of Ernexa Therapeutics Inc. (ERNA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
Price Performance
| 1 month | -8.00% |
| 3 months | -36.94% |
| Year-to-date | -86.97% |
| 1 year | -86.75% |
| 3 years | -99.52% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $71.50 |
| 52-week Low | $3.18 |
| Avg Volume (90d) | 627K |
Technical Indicators
| SMA 50 | $4.59 |
| SMA 200 | $12.01 |
| 30-day Volatility (annualised) | 63.9% |
| Price vs SMA 50 | -14.7% |
| Price vs SMA 200 | -67.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $47.00 | |
| 2025-11 | $33.75 | -28.2% |
| 2025-12 | $30.00 | -11.1% |
| 2026-01 | $30.50 | +1.7% |
| 2026-02 | $7.13 | -76.6% |
| 2026-03 | $4.98 | -30.2% |
| 2026-04 | $3.69 | -25.9% |
| 2026-05 | $10.57 | +186.4% |
| 2026-06 | $6.65 | -37.1% |
| 2026-07 | $3.28 | -50.7% |
| 2026-08 | $4.57 | +39.3% |
| 2026-09 | $3.91 | -14.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $3.91 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.45 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.11 |
| Current Ratio | 2.01 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -62.89 |